Anand Patel
@anand-88-patel.bsky.social
Leukemia & myeloid malignancy doctor. posts=mine. Repost≠endorsement. He/him. https://scholar.google.com/citations?user=kNhjy-MAAAAJ&hl=en
a thoughtful @bloodjournal.bsky.social article on recent negative Phase III studies in higher-risk MDS
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
November 14, 2025 at 1:27 AM
a thoughtful @bloodjournal.bsky.social article on recent negative Phase III studies in higher-risk MDS
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
Our NCI study of HMA +/- Iadademstat is enrolling briskly for patients with HMA-naive accelerated/blast phase MPNs and overlap syndromes!
www.cancer.gov/research/par...
www.cancer.gov/research/par...
November 11, 2025 at 11:49 PM
Our NCI study of HMA +/- Iadademstat is enrolling briskly for patients with HMA-naive accelerated/blast phase MPNs and overlap syndromes!
www.cancer.gov/research/par...
www.cancer.gov/research/par...
excited to be able to highlight our Myelomatch study for IDH2-mutated MDS at the ongoing Alliance meeting!
November 7, 2025 at 6:57 PM
excited to be able to highlight our Myelomatch study for IDH2-mutated MDS at the ongoing Alliance meeting!
Very excited to be sharing the results of our Phase II trial of TKI plus inotuzumab for Ph+ ALL as an oral presentation at the @ash.hematology.org annual meeting!
November 3, 2025 at 2:56 PM
Very excited to be sharing the results of our Phase II trial of TKI plus inotuzumab for Ph+ ALL as an oral presentation at the @ash.hematology.org annual meeting!
Fall colors are out in Chicago!
November 2, 2025 at 4:42 PM
Fall colors are out in Chicago!
excellent paper in @bloodjournals.hematology.org on the role of RAS in resistance to FLT3-inhibition and BCL2 inhibition in AML and the potential role of RAS inhibition
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
October 30, 2025 at 7:26 PM
excellent paper in @bloodjournals.hematology.org on the role of RAS in resistance to FLT3-inhibition and BCL2 inhibition in AML and the potential role of RAS inhibition
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
Thrilled to share work on outcomes of pts with acute leukemia that previously received revumenib! In 15 pts that received post-rev therapy we found:
-11 pt got Ven-containing regimens (6 HMA-VEN, 5 IC-VEN)
-CR/CRi rate of 47%
-6 pts were bridged to allo-HCT
onlinelibrary.wiley.com/doi/10.1111/...
-11 pt got Ven-containing regimens (6 HMA-VEN, 5 IC-VEN)
-CR/CRi rate of 47%
-6 pts were bridged to allo-HCT
onlinelibrary.wiley.com/doi/10.1111/...
October 27, 2025 at 12:11 PM
Thrilled to share work on outcomes of pts with acute leukemia that previously received revumenib! In 15 pts that received post-rev therapy we found:
-11 pt got Ven-containing regimens (6 HMA-VEN, 5 IC-VEN)
-CR/CRi rate of 47%
-6 pts were bridged to allo-HCT
onlinelibrary.wiley.com/doi/10.1111/...
-11 pt got Ven-containing regimens (6 HMA-VEN, 5 IC-VEN)
-CR/CRi rate of 47%
-6 pts were bridged to allo-HCT
onlinelibrary.wiley.com/doi/10.1111/...
excellent article in @bloodjournals.hematology.org on the challenges of incorporating novel therapies into the routine management of ALL!
ashpublications.org/bloodadvance...
ashpublications.org/bloodadvance...
October 21, 2025 at 12:15 PM
excellent article in @bloodjournals.hematology.org on the challenges of incorporating novel therapies into the routine management of ALL!
ashpublications.org/bloodadvance...
ashpublications.org/bloodadvance...
Thank you to the Mumbai Hematology Group for virtually inviting me to speak about accelerated/blast-phase MPNs!
October 18, 2025 at 2:24 PM
Thank you to the Mumbai Hematology Group for virtually inviting me to speak about accelerated/blast-phase MPNs!
Proud to be a part of this effort in @bloodjournals.hematology.org led by Andrew Hantel looking at the impact of inclusion criteria for AML clinical trials!
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
October 16, 2025 at 8:43 PM
Proud to be a part of this effort in @bloodjournals.hematology.org led by Andrew Hantel looking at the impact of inclusion criteria for AML clinical trials!
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
a very helpful consensus paper on how to define remission status in myelofibrosis post allo-HCT!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
October 14, 2025 at 9:11 PM
a very helpful consensus paper on how to define remission status in myelofibrosis post allo-HCT!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
October 12, 2025 at 11:35 AM
October 11, 2025 at 12:49 PM
October 10, 2025 at 11:15 AM
Day 11 - AML-based risk stratification in MPN-AP/BP treated with lower-intensity therapy
pubmed.ncbi.nlm.nih.gov/39969200/
pubmed.ncbi.nlm.nih.gov/39969200/
October 9, 2025 at 5:36 PM
Day 11 - AML-based risk stratification in MPN-AP/BP treated with lower-intensity therapy
pubmed.ncbi.nlm.nih.gov/39969200/
pubmed.ncbi.nlm.nih.gov/39969200/
October 8, 2025 at 10:57 AM
Day 9 - MRD in NPM1m AML treated with lower-intensity venetoclax-based therapy
pubmed.ncbi.nlm.nih.gov/37647641/
pubmed.ncbi.nlm.nih.gov/37647641/
October 7, 2025 at 4:52 PM
Day 9 - MRD in NPM1m AML treated with lower-intensity venetoclax-based therapy
pubmed.ncbi.nlm.nih.gov/37647641/
pubmed.ncbi.nlm.nih.gov/37647641/
October 7, 2025 at 2:19 AM
Check our work on disparities in MF outcomes led by @andrewthepalmer.bsky.social! We found:
-Lower rates of JAK inhibitor use in Black pts
-survival disparity for Black pts is mediated by structural racism
-MF risk scores don’t stratify Hispanic pt outcomes well
www.nature.com/articles/s41...
-Lower rates of JAK inhibitor use in Black pts
-survival disparity for Black pts is mediated by structural racism
-MF risk scores don’t stratify Hispanic pt outcomes well
www.nature.com/articles/s41...
October 6, 2025 at 9:46 PM
Check our work on disparities in MF outcomes led by @andrewthepalmer.bsky.social! We found:
-Lower rates of JAK inhibitor use in Black pts
-survival disparity for Black pts is mediated by structural racism
-MF risk scores don’t stratify Hispanic pt outcomes well
www.nature.com/articles/s41...
-Lower rates of JAK inhibitor use in Black pts
-survival disparity for Black pts is mediated by structural racism
-MF risk scores don’t stratify Hispanic pt outcomes well
www.nature.com/articles/s41...
October 5, 2025 at 8:22 PM
Day 6 - ldac-clad-ven in patients already treated with HMA plus Ven
haematologica.org/article/view...
haematologica.org/article/view...
October 4, 2025 at 6:01 PM
Day 6 - ldac-clad-ven in patients already treated with HMA plus Ven
haematologica.org/article/view...
haematologica.org/article/view...
October 3, 2025 at 1:56 PM
October 2, 2025 at 6:17 PM
October 1, 2025 at 8:45 PM
September 30, 2025 at 8:04 PM